SCHEMBL4675005

SCHEMBL4675005

O=C(O)/C(O)=C/C(=O)c1ccoc1Cc1ccc(F)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
POLB P06746 2/20 0.34
HSD17B10 Q99714 1/20 0.34
CTBP2 P56545 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
RAB9A P51151 2/20 0.33
HPGD P15428 1/20 0.33
LMNA P02545 3/20 0.33
MAPT P10636 3/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675011 1.00 TP53 (0.35) TP53SMN1; SMN2POLBHSD17B10CTBP2
SCHEMBL4672763 0.88 TP53 (0.47) TP53SMN1; SMN2POLBHSD17B10CTBP2
SCHEMBL4672759 0.88 TP53 (0.47) TP53SMN1; SMN2POLBHSD17B10CTBP2
SCHEMBL4676250 0.87 CYP2C19 (0.40) TP53SMN1; SMN2POLBHSD17B10ALDH1A1
SCHEMBL4676253 0.87 CYP2C19 (0.40) TP53SMN1; SMN2POLBHSD17B10ALDH1A1
SCHEMBL4675037 0.86 ITGB1 (0.35) TP53SMN1; SMN2POLBHSD17B10ALDH1A1
SCHEMBL4675032 0.86 ITGB1 (0.35) TP53SMN1; SMN2POLBHSD17B10ALDH1A1
SCHEMBL16921547 0.86 CA12 (0.38) TP53SMN1; SMN2POLBHSD17B10ALDH1A1
SCHEMBL752081 0.86 CA12 (0.38) TP53SMN1; SMN2POLBHSD17B10ALDH1A1
SCHEMBL4670971 0.86 HCAR2 (0.39) SMN1; SMN2POLBALDH1A1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 TP53 999/4885SMN1; SMN2 4107/4885POLB 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.